COVID-19 Update

Our people are our most valued resource. During these uncertain times, HiFiBiO Therapeutics remains committed to the health, safety and well-being of our employees, partners and guests. We continue to monitor local government guidance and have implemented enhanced safety measures at each of our sites in Cambridge, Paris, Shanghai and Hong Kong.

We are also committed to the global humanitarian effort on combating COVID-19 by leveraging our robust antibody drug discovery and development engine to identify solutions for the treatment and prevention of the SARS-COV-2 infection.